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Abstract
The search for the genomic sequences involved in human cancers can be greatly facilitated by
maps of genomic imbalances identifying the involved chromosomal regions, particularly those
that participate in the development of occult preneoplastic conditions that progress to clinically
aggressive invasive cancer. The integration of such regions with human genome sequence
variation may provide valuable clues about their overall structure and gene content. By extension,
such knowledge may help us understand the underlying genetic components involved in the
initiation and progression of these cancers. We describe the development of a genome-wide map
of human bladder cancer that tracks its progression from in situ precursor conditions to invasive
disease. Testing for allelic losses using a genome-wide panel of 787 microsatellite markers was
performed on multiple DNA samples, extracted from the entire mucosal surface of the bladder and
corresponding to normal urothelium, in situ preneoplastic lesions, and invasive carcinoma. Using
this approach, we matched the clonal allelic losses in distinct chromosomal regions to specific
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phases of bladder neoplasia and produced a detailed genetic map of bladder cancer development.
These analyses revealed three major waves of genetic changes associated with growth advantages
of successive clones and reflecting a stepwise conversion of normal urothelial cells into cancer
cells. The genetic changes map to six regions at 3q22–q24, 5q22–q31, 9q21–q22, 10q26, 13q14,
and 17p13, which may represent critical hits driving the development of bladder cancer. Finally,
we performed high-resolution mapping using single nucleotide polymorphism markers within one
region on chromosome 13q14, containing the model tumor suppressor gene RB1, and defined a
minimal deleted region associated with clonal expansion of in situ neoplasia. These analyses
provided new insights on the involvement of several non-coding sequences mapping to the region
and identified novel target genes, termed forerunner (FR) genes, involved in early phases of cancer
development.
Keywords
forerunner genes; whole-organ histologic and genetic mapping; high-resolution mapping with
SNPs; dual-track pathway of bladder cancer development; apoptosis
We have developed a strategy to identify genetic hits across the entire mucosa of an affected
organ relative to cancer progression, from in situ precursor conditions to invasive disease, on
a total genomic scale. We used the approach, which we refer to as whole-organ histologic
and genetic mapping (WOHGM), to identify clonal hits associated with growth advantage,
thus tracking the development of human bladder cancer from occult in situ lesions. Human
bladder carcinoma was used as a model of a common epithelial malignancy that develops by
progression of microscopically recognizable intraurothelial preneoplastic conditions known
as dysplasia and carcinoma in situ.1
Carcinoma of the bladder is the fifth most frequent human cancer, primarily affecting people
over the age of 50 years, and accounts for approximately 3% of all cancer-related deaths.2,3
The common carcinomas of the bladder develop in its epithelial lining (urothelium) and are
referred to as transitional cell carcinomas (TCCs). They arise via two distinct, but sometimes
overlapping pathways, papillary and non-papillary.4,5 Approximately 80% of urinary
bladder tumors are superficially growing papillary lesions that originate from urothelial
hyperplasia. They frequently recur after excision but usually do not aggressively invade the
bladder wall or metastasize. Most aggressive bladder cancers are of the solid, non-papillary
type, which originate from in situ precursor conditions such as dysplasia and carcinoma in
situ. They aggressively invade the bladder wall and have a high propensity for metastasis.
Exposure to environmental, industrial, and habitual chemical carcinogens has a well-
established etiologic relation to bladder cancer.6 Cigarette smoking is the most important
risk factor, thought to contribute to more than 50% of cases, while occupational or
environmental exposure to aromatic amines may account for an additional 25% of the total.
7,8
The maps of several individual chromosomes and the preliminary genetic model of bladder
carcinogenesis based on deletional maps of chromosomes 4, 8, 9, 11, and 17 constructed by
WOHGM were reported previously.9–15 The genome-wide WOHGM data were included in
our recent publication focused on the concept of alternative target genes termed forerunner
(FR) genes located near the model tumor suppressor, RB1.16
Here, we report on the construction of the genome-wide map that tracks human bladder
cancer development from in situ precursor conditions to clinically aggressive invasive
disease. We present the principles of WOHGM and describe the integration of deletional
recombination-based chromosomal maps with the human genome sequence maps using
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chromosome 13 as an example. This approach was extended to the remaining autosomes and
permitted the construction of a genome-wide map of bladder cancer as well as the
identification of the six chromosomal regions critical for its development.
Finally, we present high-resolution mapping with single nucleotide polymorphism (SNP)
markers of one of the critical chromosomal regions that contains the model tumor
suppressor, RB1 on chromosome 13q14, which defined a minimal deleted segment
associated with clonal expansion of in situ neoplasia. The analysis of its genomic content
provided insight into the role of both non-coding sequence and FR genes involved in early
phases of bladder carcinogenesis.
MATERIALS AND METHODS
Overall Strategy
The overall strategy used to construct a genome-wide map of bladder cancer development is
summarized in Figure 1. For WOHGM the initial primary screening with hypervariable
DNA markers was performed on paired non-tumor (peripheral blood) and representative
invasive tumor DNA samples of five cystectomy specimens. Markers showing loss of
heterozygosity (LOH) were selected for secondary screening on all mucosal samples of the
same cystectomy specimens. The pattern of LOH of chromosomes 1–22 was used to
construct a genome-wide map of bladder cancer development and to identify six
chromosomal regions critical for clonal expansion of in situ neoplasia. Since these six
regions were identified by testing five cystectomy specimens, we validated the frequency of
their involvement on paired voided urine and peripheral blood DNA (PBDNA) samples
from 63 bladder cancer patients.
We concentrated our subsequent high-resolution WOHGM studies on one of the critical
chromosomal regions spanning 26.9 Mb around a model tumor suppressor RB1. These
studies defined a 1.34 Mb minimal deleted region flanking RB1, which contained several
positional alternative target FR genes putatively involved in clonal expansion of in situ
neoplasia. The WOHGM studies were verified on 111 paired bladder tumors and PBDNA.
The organization of high-resolution mapping studies followed by the analysis of genomic
content of the 13q14 minimal deleted region and its candidate FR genes is shown in Figure
2.
Human samples and cell lines—Bladder tumor samples used in our study were
classified according to the three-tier histologic tumor grading system of the World Health
Organization17 and were dichotomized into low-grade (grade 1–2) and high-grade (grade 3)
tumors.5 The growth pattern of papillary versus non-papillary or solid and the depth of
invasion were also recorded. Levels of invasion were defined according to the TNM staging
system.18 T1 tumors were substaged into superficial (Ta–T1a) and invasive (T1b and higher)
groups.19,20 The precursor intraurothelial lesions were dichotomized into low- and high-
grade categories labeled LGIN and HGIN, respectively, as previously described.5 All human
tissues were collected under protocols reviewed and approved by the Institutional Review
Boards of the participating institutions and their sharing was carried out under the inter-
institutional material transfer agreements.
WOHGM was performed on radical cystectomy specimens from five patients with
previously untreated sporadic high-grade (grade 3) invasive TCC. All patients were men,
ranging in age from 47 to 78 years (mean = 66.4±11.9 years s.d.). The genome-wide
WOHGM with hypervariable DNA markers was used to identify six chromosomal regions
critical for clonal expansion of in situ neoplasia. The frequency of their involvement was
verified on paired voided urine and PBDNA samples from 63 bladder cancer patients. The
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63 patients were comprised of 46 men and 17 women, with ages ranging from 45 to 86 years
(mean age = 68.5 ±10.6 years s.d.). Among 63 TCCs, 28 were low-grade (grade 1–2)
superficial (Ta–T1a) and 35 were high-grade (grade 3) invasive (T1b and higher) tumors. For
32 of these patients, the voided urine was collected at the time of initial diagnosis. The
remaining 31 patients had a history of bladder tumor removal by transurethral resection and
were disease free at the time of urine collection.
The high-resolution WOHGM with SNP markers was performed on the RB1-containing
13q14 region using the same five cystectomy specimens. The high-resolution WOHGM
studies were verified on an additional 111 paired samples of bladder tumors and PBDNA.
The 111 patients were comprised of 86 men and 25 women (mean age 66.1±10.5 years s.d.).
Among 111 TCCs, 20 were low-grade (grade 1–2) superficial (Ta–T1a) and 91 were high-
grade (grade 3) invasive (T1b and higher) tumors.
We analyzed the sequences, expression, and methylation status of the candidate FR genes
using cystectomy specimens, bladder cancer cell lines, and paired samples of adjacent
urothelium and bladder tumors. In the first instance, the human bladder cancer cell lines
UC1, UC2, UC3, UC6, UC9, UC10, UC12, UC13, UC15, UC16, and UC17, and normal
human urothelial cells were established by us and the SV40 immortalized human urothelial
cell line, SVHUC was obtained from Dr CA Reznikoff; cells were cultured as previously
described.21–25 In the second instance, the same five cystectomy specimens utilized for
genome-wide mapping studies were used for geographic sequencing of selected candidate
FR genes. In the third instance, the expression and methylation studies were conducted on
paired samples of adjacent urothelium and tumor from patients with bladder cancer. In
addition, large-scale testing for methylation of ITM2B and sequencing of P2RY5 were
performed on multiple bladder tumor samples as previously described.16 Because in some
instances point mutations of P2RY5 affected the germ line, and our patients or their family
members were not able to provide meaningful familial histories, we performed additional
sequencing analyses of index cases from 46 families with high incidences of various
common malignancies. The clinical data with a list of tumors affecting these families are
provided in Supplementary Table 1.
To verify that loss of FR gene function is a frequent phenomenon in human carcinogenesis,
the sequence, methylation status, and expression of RB1 and selected candidate FR genes
were tested in 62 cell lines derived from several groups of human malignancies. We
established cell lines or obtained them from the American Type Culture Collection
(Manassa, VA, USA) and cultured them as previously described.26,27
WOHGM with hypervariable DNA markers—A genome-wide search for chromosomal
regions, whose losses are associated with growth advantage and clonal expansion of in situ
neoplasia, was performed by WOHGM using hypervariable DNA markers and human
cystectomy specimens as previously described.9–15 In brief, each fresh cystectomy specimen
was opened longitudinally along the anterior wall of the bladder and pinned down to a
paraffin block. The entire bladder was divided into 1 cm × 2cm rectangular samples and
frozen in OCT. Several 5-μm thick sections were cut from each frozen block. One frozen
section from each block was stained with hematoxylin and eosin to evaluate the distribution
of in situ precursor lesions and TCC microscopically. The remaining unstained sections
were stored at −70°C until used for immunohistochemical studies. The whole-organ maps of
cystectomy specimens with the distribution of in situ precursor lesions and TCC are shown
in Figure 3. For DNA extraction, the mucosal samples were defrosted and washed three
times in PBS. The mucosal surface of each sample containing microscopically normal-
appearing urothelium or in situ precursor lesions (LGIN and HGIN) was scraped with a
razor blade and transferred into a conical tube containing PBS. In samples with invasive
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TCC, the tumor tissue was dissected from the frozen block to minimize contamination with
non-tumor cells. Only those samples that yielded more than 90% microscopically
recognizable intact urothelial tumor cells were used for DNA extraction. This procedure
provided 49, 39, 65, 42, and 39 DNA samples, respectively, from the five cystectomies. As a
control, DNA extracted from the peripheral blood lymphocytes and/or from normal tissue in
the resected specimen of each patient was used.
WOHGM was performed with a set of primers for 787 DNA markers (mostly
microsatellites) mapping to chromosomes 1–22 and based on the integrated sex-averaged
microsatellite map from Genethon (version March 1996) and updated by the Cooperative
Human Linkage Center (version 4.0) (Research Genetics, Huntsville, AL, USA). Markers
mapping to chromosomes X and Y were not tested. Testing with DNA hypervariable
markers was performed in two steps. In the first step, all 787 markers were tested on paired
samples corresponding to non-tumor and invasive tumor DNA from the same individual in
five cystectomy specimens. Those markers that showed allelic loss were tested on all
mucosal samples of the same cystectomy. The allelic patterns of markers were resolved on
6% polyacrylamide gels after their amplification using the PCR. An additional set of 80
microsatellite DNA markers mapping to the six chromosomal regions associated with clonal
expansion of neoplasia was tested on DNA extracted from voided urine sediments from 63
patients with bladder cancer. The raw data used to assemble the genomic map of bladder
cancer development are summarized in Table 1.
Analysis of Human Genome Sequence Databases Spanning the Deleted Regions
During generation of these data, resources defining the human genome evolved from
integrated genetic and radiation hybrid maps to physical maps, to the draft sequence and
finally to the finished human genome sequence. We primarily used the Santa Cruz browser
(http://genome.ucsc.edu) and secondarily, the browsers and maps available from Ensembl
(http://www.ensembl.org) and the NCBI Integrated Map Viewer
(http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?taxid =9606) to place the
hypervariable markers on the genomic sequence using their available tracks. We also used
these resources to extract the relevant known and predicted genes, EST clusters, SNPs, and
CpG islands corresponding to these regions of interest. Finally, for markers not present on
tracks, we used electronic PCR, in silico PCR, or BLAST for placement.28–30
Statistical Analysis
The data were organized and analyzed as previously described.14 In brief, the information
on LOH of individual markers was entered into a database and superimposed over the
histologic maps. Initial data consisted of chromosomal vectors with a list of markers with
their LOH and coordinates for locations of mucosal samples, which could be used to plot the
distribution of LOH to microscopically classified urothelial changes. By superimposing
plots of LOH over the histologic maps, we identified the areas of bladder mucosa with
altered markers and analyzed their relationship to intraurothelial precursor conditions and
invasive cancer.
The relationship between altered markers and the progression of urothelial neoplasia from
precursor conditions to invasive cancer was initially tested by a binomial maximum
likelihood analysis, and the significance of the relationship was expressed as a logarithm of
odds (LOD) score as previously described.10–13,16,31 We chose LOD scores because they
represent a powerful method of likelihood analysis that can verify the statistical significance
of the relationship among patterns of sequential events. The LOD scores were applied in
their generic mathematical sense as likelihood tests of events. In sporadic cancer when
microscopically defined stages of cancer progression are used as standards of sequential
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events and there is mitotic transmission of the phenotype, the null hypothesis is more
appropriately verified at a recombination factor differing from 0.5. Hence, combined LOD
scores for all cystectomies were calculated at variable θ = 0.01, 0.5, and 0.99. A pattern of
LOD scores ≥3 at θ = 0.01 or 0.99 and LOD scores <3 at θ = 0.5 for the same marker was
considered significant. The strongest association between altered marker and neoplasia was
when a LOD score was ≥3 and θ = 0.99 and 0.5 and <3 at θ = 0.01. Stringency 1 designated
LOD scores for specific stages of neoplasia. Stringency 2 designated LOD scores for
progression to higher stages of neoplasia. The relationships among LOH in individual loci
and various clinico-pathological parameters of tumors and voided urine samples were tested
by Gehan’s generalized Wilcoxon and log-rank tests (P≤0.05 was considered significant).
The genome-wide patterns of LOH in relation to geographic distribution of preneoplastic
conditions and invasive cancer in individual cystectomies were generated and analyzed by
the nearest neighbor algorithm.32
High-resolution mapping with SNPs of the 13q14 region containing RB1—
WOHGM with SNPs was performed as previously described.14 In brief, the genome
sequence corresponding to the microsatellite-defined region of LOH in 13q14 was
assembled. The positions of all currently defined SNPs mapping within the 26.9-Mb region
around RB1 (approximately 20 000 SNPs) were identified in the SNP database
(http://www.ncbi.nlm.nih.gov/SNP). The integrated gene and SNP map was used to select
661 SNPs mapping within a 26.9-Mb segment around RB1. Allelotyping of SNPs was
performed and analyzed using an automated pyrosequencing instrument PSQ96MA (Biotage
AB, Uppsala, Sweden).33,34 The SNPs were sequenced using DNA samples corresponding
to whole-organ histologic maps of five cystectomy specimens originally used for
microsatellite-based WOHGM. The minimal deleted region associated with clonal
expansion of in situ neoplasia was identified by the alignment of clonal plaque-like deleted
segments from individual cystectomies. Additional allelotyping of 100 SNPs mapping
between the ESD and C13orf1 genes and spanning approximately 3.16 Mb around RB1 was
performed using SNP multiplex (SNPlex™; Applied Biosystems, Foster City, CA, USA)
technology following the manufacturer’s protocol available at
http://docs.appliedbiosystems.com/pebiodocs/04360857.pdf.
Immunohistochemical staining for RB protein—RB protein status was determined
by immunohistochemical analysis of frozen sections using the RB-WL-1 polyclonal anti-RB
antibody as previously described.35,36 In brief, RB-WL-1 is a rabbit polyclonal antibody
produced against a peptide encoded by exon 10 of RB1. In western blot analyses, to
recognize both phosphorylated and underphosphorylated forms of the RB protein, staining
could be completely blocked by an excess of the immunizing peptide. For
immunohistochemical staining, frozen sections stored at −70°C were defrosted for 30 min at
room temperature and fixed in cold methanol: acetone (1:1 volume) at 4°C for 10 min. After
being rinsed three times in PBS, they were incubated for 15 min with 0.1% H2O2 in PBS,
followed by a 15-min incubation with avidin blocking solution and a 15-min incubation with
biotin blocking solution (Vector Laboratories Inc., Burlingame, CA, USA). The sections
were then blocked with 10% goat serum in 2% BSA-PBS for 30 min and incubated
overnight at 4°C with RB-WL-1 polyclonal anti-RB antibody at 0.25 μg/ml in 2% BSA-
PBS. The bound antibody was visualized by avidin–biotin complex assay using a
VECTASTAIN ABC kit (Vector Laboratories Inc.) with 3,3′-diaminobenzidine as the
chromogen.
Expression assays for RB1 and candidate FR genes—Quantitative RT-PCR was
used to analyze the expression levels of RB1 and candidate FR genes in cell lines and paired
samples corresponding to adjacent urothelium and bladder tumor samples as described
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previously.16 For RT-PCR, cDNA was synthesized from 2 μg of total RNA using the
TaqMan™ RT reagents following the manufacturer’s protocol (Applied Biosystems). The
primers and fluorescent probes for each gene were designed using the Assays-by-Design
provided by Applied Biosystems. RT-PCR analysis was performed on a Perkin-Elmer/
Applied Biosystems 7700 Prism apparatus using 18S RNA as an internal normalization
standard. In addition to 18S, the expressions of three housekeeping genes (large ribosomal
protein, cyclophylin A, and β-actin) were used to calculate the 90% confidence intervals.
The expression levels of each gene were compared to their baseline expression in the
corresponding normal tissue. We considered the FR genes to be inactivated when their level
of expression was reduced by ≥75% or ≥4-fold.
DNA sequence analysis—We sequenced the PCR-amplified exons of RB1 and
candidate FR genes from tumor and control samples by Sanger dideoxy sequencing using
Big-Dye Terminator Chemistry. PCR products were purified from unincorporated primers
and dNTPs by using exonuclease I and shrimp alkaline phosphatase and subsequent
sequencing reactions were analyzed with an ABI 3730 sequencer (Applied Biosystems).
Sequence was obtained from both strands and potential mutations were identified using the
Mutation Surveyor software (Softgenetics, State College, PA, USA) and confirmed by
visual inspection. For selected samples, the presence of mutations was confirmed by
sequencing of subcloned amplified exons. Pyrosequencing was used to confirm the loss of a
wild-type P2RY5 allele in bladder mucosa and to confirm the presence of the same
mutations among the members of families carrying germline mutations of P2RY5.
Pyrosequencing after laser microdissection (SlmicroCut Molecular Machines and Industries,
Knoxville, TN, USA) of paraffin-embedded tumor tissue was also used to document the loss
of a wild-type P2RY5 allele in tumors affecting family members carrying germline
mutations of P2RY5.33,34
Testing for germline mutations of known tumor suppressor genes in families
with hereditary cancer—Since 46 families with hereditary cancer used for testing of
germline mutations of P2RY5 were affected primarily by hereditary breast cancer and some
showed the pattern of transmission as well as types of cancers suggestive of the involvement
of other known cancer predisposing genes, germline mutations involving BRCA1, BRCA2,
p53, PTEN, hMLH1, and hMSH2,37–43 were excluded by testing the PBDNA of the affected
index cases. The PBDNA of the same index cases was used for testing for germline
mutations of P2RY5. The involvement of BRCA1 and BRCA2 was excluded in all 46
families by partial sequencing of exons 11 and 13 for BRCA1 and exons 10 and 11 for
BRCA2.37 In addition, both genes were tested for the presence of mutations frequently seen
in hereditary breast cancer affecting Ashkenazi Jewish families.38–45 The involvement of
these genes was additionally tested by protein termination assays.46,47 Some of the families
included in the analyses were also tested for germline mutations of p53, PTEN, hMLH1, and
hMSH2 by sequencing.38,43 In one family with missense germline mutations of P2RY5 that
resulted in amino-acid substitutions, complete sequencing of p53, BRCA1/2, and of RB1 of
the index cases was performed and disclosed the wild-type sequence for all three genes.
Methylation assays—We used combined bisulfite restriction analysis (COBRA) and
methylation-sensitive PCR to identify methylated CpG islands containing the putative
promoters of candidate FR genes. The bisulfite treatment of DNA and design of the assay
were previously described.48,49 In brief, bisulfite-modified DNA was amplified by PCR and
the amplified products were incubated with restriction enzymes that digest only methylated
alleles. The methylation status of CpG sites within the putative promoter regions was
confirmed by sequencing of sodium bisulfite-modified DNA. To verify whether expression
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of FR genes could be restored by promoter demethylation, cell lines showing
hypermethylated FR gene promoters were treated with 5-aza-2′-deoxycytidine.
RESULTS AND DISCUSSION WOHGM
Conventional histologic mapping of invasive, clinically evident cancer and adjacent tissues
combined with clinical and epidemiological data gathered during the last 50 years provides
compelling evidence that epithelial cancers develop from precursor in situ conditions
designated as dysplasia or carcinoma in situ.50 These conditions progress to invasive cancer
by multiple cumulative molecular events. In fact, the incipient hits occur in normal tissue
and many are antecedent to the development of microscopically identifiable precursor
lesions. Although genetic models of progression from pre-malignant conditions have been
proposed for several human malignancies, including bladder cancer, the specific events
leading to the development and progression of human neoplasia have not been defined.51–57
Analysis of genomic imbalances can guide us to those chromosomal regions that contain
genes and non-coding sequences playing a role in tumor development. The functional
implications of such imbalances and consequently their pathogenetic significance are largely
unknown. Moreover, it is unclear which of the imbalances are primary events relevant to
disease progression and which are redundant hits dragged through the progression by mere
cosegregation. In familial disorders including cancer predisposing syndromes, a
cosegregation of genetic hits with diseased phenotype identifies a predisposing locus and
may guide subsequent positional cloning of a target gene.58,59 Unfortunately, the powerful
concepts of genetic linkage analysis in pedigrees cannot be used in the vast majority of
human cancers, owing to their primarily sporadic nature. In cancers that develop from
preneoplastic conditions, however, the early events can instead be deduced from the
geographic relationship between genomic imbalance and precursor in situ conditions (Figure
4a–c).9–16 The similarity of alterations such as loss of the same allele or the presence of
identical molecular alterations in multiple samples corresponding to precursor conditions
and invasive cancer disclose their clonal relationship. Taken together, these identify genetic
hits that provide growth advantage related to a particular clone of cells collectively referred
to as clonal expansion.
By superimposing distributions of genetic hits such as allelic loss over the histologic maps
of the entire mucosa, the two basic patterns can be identified: scattered, in which several
isolated foci are present; and plaque-like, where a large contiguous area of identical genetic
changes are found. The scattered isolated foci showing limited clonal expansion of
preneoplastic cells are typically not considered to be functionally relevant for disease
development and progression (data not shown). The hits that form plaque-like areas
associated with clonal in situ expansion of preneoplastic cells involving large areas of
mucosa that encompass not only invasive cancer and precursor conditions but also adjacent
areas of microscopically normal epithelium represent early events associated with the
development of incipient occult phases of neoplasia. On the opposite side of the spectrum
are hits restricted to invasive carcinoma and adjacent areas of severe dysplasia or carcinoma
in situ, representing late events associated with the progression to invasive cancer (Figure
4a–c).
For WOHGM, a cystectomy specimen was divided into approximately 30–60 mucosal
samples, each covering 2 cm2 (1 cm × 2 cm) of mucosal area and corresponding to
microscopically verified normal urothelium, precursor intraurothelial conditions, or invasive
carcinoma. The uroepithelial lining of the bladder was stripped from the underlying stromal
tissue by simple mechanical scraping, providing 99% pure urothelial cell suspensions as
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determined by microscopic evaluation. Such samples typically yielded 5–10 μg of genomic
DNA for genome-wide PCR-based mapping studies.
Microsatellite-Based Whole-Organ Histologic and Genetic Map of Chromosome 13
Chromosome 13 was selected as an example because it contains a prototypic tumor
suppressor gene, the retinoblastoma (RB1) gene.60,61 The RB1 locus was originally mapped
by chromosomal deletion and genetic linkage in a familial form of retinoblastoma62–64 and
the target RB1 gene was identified using a positional cloning strategy.65–68 The inactivation
of both RB1 gene alleles in two distinct steps during the development of retinoblastoma
validated the ‘two-hit hypothesis’; a key concept of reverse genetics that provided the
impetus for the positional cloning of other genes predisposing to various diseases.69,70 The
RB1 gene was subsequently proven to play a major role in the development of many
sporadic human cancers including bladder carcinoma.71,72 Several studies indicate that the
inactivation of RB1 in bladder neoplasia parallels the onset of severe dysplasia/carcinoma in
situ that progresses to invasive disease and is associated with an aggressive form of bladder
cancer with high propensity for distant metastasis.73,74 We hypothesized that if our method
and approach showed clonal allelic loss of markers mapping to within and around the RB1
gene, and involving large areas of bladder mucosa, it would be reasonable to assume that
similar alterations in other loci would guide us to novel tumor suppressor-like genes playing
a role in early phases of bladder neoplasia.
The initial analysis of paired normal and tumor DNA samples identified LOH in all five
cystectomies examined, and involved 14 of 42 tested markers mapping to chromosome 13.
The binomial likelihood analysis of LOH distribution patterns across the bladder mucosa
showed that allelic losses related to the development of urothelial neoplasia clustered in four
distinct regions of chromosome 13. The deleted regions defined by their flanking markers,
their predicted size, and a list of markers within regions containing LOH are shown in
Figure 5a and b.
A deleted segment mapping to 13q14, flanked by D13S263 and D13S276 and containing the
RB1 gene, showed allelic loss in four of the five cystectomies. Allelic losses in this region
were associated with clonal expansion involving large areas of bladder mucosa,
encompassing not only invasive cancer and preneoplastic conditions but also extending to
areas of microscopically normal urothelium. The allelic losses of markers mapping to within
and around the RB1 gene formed large almost identical overlapping plaques of clonal
expansion.
The three remaining segments of allelic losses mapping to 13q12 and 13q13 were associated
with some limited clonal expansion and formed several separate foci which were not strictly
geographically related to precursor in situ lesions.
The entire microsatellite recombination-based deletional maps of chromosomes 1–22 are
submitted as Supplementary Figure 1.
Genome-Wide Map of Bladder Cancer Development
The genome-wide search for chromosomal allelic losses using a WOHGM strategy was
performed to produce a detailed map of bladder cancer development from occult
preneoplastic conditions to invasive disease (Figure 6). We hypothesized that such an
approach would also facilitate the analysis of global genetic alterations in multistep bladder
carcinogenesis and would permit the identification of the limited number of critical hits that
drive the transformation of normal urothelial cells to malignant cells.
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The search for losses of genetic material was performed with 787 markers mapping to
chromosomes 1–22. Testing was performed on 234 DNA samples from five cystectomies
corresponding to microscopically normal urothelium (n = 53), LGIN (n = 82), HGIN (n =
50), and invasive TCC (n = 49). Initially all 787 markers were tested on paired DNA
samples corresponding to invasive bladder carcinoma and paired normal DNA from
peripheral blood lymphocytes. LOH was identified in 194 markers that were subsequently
tested on DNA from all mucosal samples from the five cystectomies.
While 72 markers exhibited patterns of LOH that could not be related to the development of
progression of bladder neoplasia, the clonal allelic loss of 122 markers clustered in 59
distinct chromosomal regions and had a relationship to the geographic distribution of
preneoplastic conditions or invasive cancer, as defined by the binomial maximum likelihood
analysis. Of these, 83 were associated with expansion of a phenotypically normal clone or
early in situ preneoplastic conditions consistent with LGIN. The clonal allelic losses of the
26 remaining markers may be related to the development of HGIN or invasive cancer.
When we analyzed the genome-wide distribution of allelic losses in individual cystectomies,
it became evident that all areas of bladder mucosa with LOH were geographically related.
Even those markers that exhibited allelic loss across several separate areas of mucosa were
in fact related and represented successive subclones emerging from a large clonal field
change as defined by the nearest neighbor analysis. Thus, losses of genetic material
associated with clonal expansion of urothelial cells could be viewed as a succession of hits
associated with growth advantage that parallel the gradual change of normal cells to cancer
cells.
We identified three major waves of hits that may correspond to the phases of tumorigenesis
identified in experimental models and referred to as initiation, promotion, and progression
(data not shown). The first wave contributed to clonal expansion of phenotypically normal-
appearing urothelial cells that involved large portions of bladder mucosa. The second wave
presumably provided additional growth advantage and was associated with clonal expansion
of cells showing the first microscopically recognizable features of dysplasia. The third and
last wave led to a fully transformed phenotype and was associated with the onset of severe
dysplasia/carcinoma in situ. Further advancement to invasive cancer was not associated with
an additional major loss of genetic material.
The complex pattern of allelic losses identified by WOHGM most likely reflected the
overall genomic instability. Many of these alterations were dragged through the progression
sequence by mere cosegregation with those hits that were functionally relevant to the
development of neoplasia. To identify those critical changes that were most likely driving
tumorigenesis, we searched our data for overlapping plaques of clonal allelic losses
demonstrating a strict geographic relationship to the two major phases of urothelial
neoplasia that are most critical for the development of bladder cancer (Figure 7a and b). The
first group consisted of alterations associated with expansion of a dominant clone with no or
minimal phenotypic change, which involved large areas of bladder mucosa. The second
group consisted of alterations associated with the development of successive clones showing
a fully transformed phenotype, ie, those that were related to onset of severe dysplasia/
carcinoma in situ progressing to invasive cancer. We identified clonal allelic losses with
such characteristics in four of the five tested cystectomies, and each one of them showed a
unique combination of changes mapping to distinct chromosomal regions (Figure 8a). This
indicates that the paths and the sequence of events that urothelial cells take on their way to
malignancy varied widely in individual cancers. When constellations of putative critical
losses from four cystectomies were analyzed it became evident that six chromosomal
regions, mapping to 3q22–q24, 5q22–q31, 9q21–q22, 10q26, 13q14, and 17p13 and
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containing well-known target genes with a tumor suppressor function, were involved in
more than one case and may represent six critical hits driving the development of human
bladder cancer (Figure 8a). This observation was confirmed by the testing of 80
hypervariable DNA markers mapping to the six critical chromosomal regions, on voided
urine samples from 63 patients with bladder cancer (Figure 8a and b). LOH affecting at least
one of the critical chromosomal regions could be identified in 98% of the samples. The
frequency of LOH in each of the chromosomal regions was similar in patients with clinically
evident tumor and in patients with history of bladder tumor removed by a transurethral
resection (Figure 8c). The frequency of LOH was also similar in low-grade (grade 1–2)
superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b and higher) tumors (Figure 8d).
Synchronous LOH involving 2–5 critical chromosomal regions was present in
approximately 80% of bladder tumors (Figure 8e).
The identification of clonal allelic losses mapping to distinct regions of various
chromosomes with almost identical geographic distribution suggests that they were either
synchronous, or occurred at a high rate involving closely related successive generations of
cells. This in turn implies an unsteady, fluctuating rate of events with waves of genetic hits
followed by more stable periods of clonal expansion in tumor development. Our data
document that human tumorigenesis is far more complex than it appears from the
epidemiologic data,75,76 and provides evidence that a limited number of critical steps (at
least six) are required and can be accompanied by a highly variable constellation of genome-
wide hits, which act in concert.
High-Resolution Mapping of RB1 Region
In this section, we review our previously published data on high-resolution mapping of the
13q14 region, and the concept of alternative target FR genes contiguous to RB1 involved in
clonal expansion of in situ neoplasia.16 We also provide new mapping data and analyses
further supporting the concept of FR genes and discuss novel candidate FR genes mapping
around RB1. In addition, we discuss the non-coding genomic content of the RB1 flanking
region and putative role of its unique non-coding sequences in the development of bladder
cancer.
Identification of minimally deleted region flanking RB1—To identify prototypic
genes and non-coding sequences that may drive the initial clonal expansion of intraurothelial
neoplasia, we concentrated our efforts on the 13q14 region, which contains the model tumor
suppressor gene, RB1. Initially, the 26.9-Mb deleted region defined by hypervariable DNA
markers was integrated with the physical map and ultimately with the human genome
sequence database. The target region contains over 20 000 SNPs and we selected 661,
preferentially located within or around the known and predicted genes, and including 34
SNP mapping within the RB1 gene. Whole-organ allelotyping of SNPs using the
pyrosequencing method was performed in three sequential steps. In the first step, all 661
SNPs of normal genomic DNA from the same individual were sequenced. The number of
informative polymorphic SNPs ranged from 76 to 101 in individual cystectomies. In the
next step, the polymorphic SNPs were tested on paired normal–invasive tumor samples, and
losses of polymorphism (LOP) were identified in all five cystectomies. In the final step,
those SNPs that showed LOP were tested on all mucosal samples. An example of high-
resolution mapping with SNPs in one cystectomy specimen is shown in Figure 9a–d. When
the whole-organ maps of allelic losses identified by SNPs and hypervariable markers were
integrated with RB1 sequencing data and RB protein expression patterns, it became evident
that a loss of DNA that affected RB1 and flanking regions was an early event in bladder
neoplasia (Figure 10a–e). This loss was associated with clonal expansion that formed a
plaque involving large areas of bladder mucosa, and was not uniformly associated with the
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inactivation of the second RB1 allele (Figure 10b–e). In those cases in which deletion of one
RB1 allele was associated with the inactivation of the second allele by a point mutation
accompanied by loss of RB protein expression, the inactivation was a later event
corresponding to onset of severe dysplasia/carcinoma in situ progressing to invasive
carcinoma (Figure 10b and e).
The patterns of integrated LOH and LOP identified by microsatellite and SNP markers,
respectively, from five cystectomy specimens defined a minimal region of 1.34 Mb
associated with clonal expansion of in situ neoplasia around RB1. Since this region was
defined by WOHGM using five cystectomies, we further investigated the frequency of its
involvement in 111 paired samples of bladder tumors and PBDNA by the allelotyping of
100 SNPs mapping to a 3.16-Mb segment around RB1 (Figure 11a and b). The position of
the segment with the most frequent LOP identified by this approach, overlapped with the
position of the region associated with clonal expansion was initially found by WOHGM.
LOP involving 3.16-Mb segment flanking RB1 could be detected in 55% of the 111 TCC
samples. In 28% of those cases, it contiguously involved RB1 and its flanking regions. In an
additional 19% of all tumor samples, it was restricted to regions flanking RB1. LOP
involving this region was equally frequent in the two pathogenetic subsets of bladder
cancers, and could be documented in 47% of low-grade (grade 1–2) superficial (Ta–T1a) and
58% of high-grade (grade 3) invasive (T1b and higher) TCCs (P = 0.5). In contrast, the
inactivation of RB1 as documented by the absence of RB protein expression in tumor cells
by immunohistochemical analysis with the remaining mutant RB1 allele revealed by DNA
sequencing was predominantly seen in high-grade invasive TCC.
These data supported the hypothesis that genes or non-coding sequences located near the
model tumor suppressor, RB1, may contribute to the development of bladder cancer by
providing growth or survival advantage to the in situ neoplasia.
Genomic content of RB1 flanking region—To examine the genomic context of the
minimal deleted region and its associated breakpoints, we performed a comprehensive
analysis of the genomic content and sequence characteristics within the 3.16-Mb segment
surrounding the RB1 locus (Figure 11c–j).
Nonallelic homologous recombination (NAHR) is a major mechanism involved in
rearrangements during mitotic crossover and DNA break repair causing somatic deletions
frequently seen in sporadic human cancer.77 NAHR between similar sequences in the same
orientation leads to a reciprocal deletion and duplication between the chromosomes
involved. A primary source of these similar sequences is mobile retrotransposon elements
such as Alus, which comprise about 11% of the human genome.78 We analyzed the LOP
region for putative sequences predisposing to NAHR by identifying similar sequences in the
same orientation using Human Chained Self Alignments (University of California Santa
Cruz (UCSC) Genome Browser) (Figure 11c). Two large partially overlapping regions
bounded by similar sequences were identified. Potential NAHR region 1 (676 kb) is
bounded by 474- and 429-bp segments that are primate specific, share 70% similarity and
are comprised of ~38% long terminal repeat (LTR) retrotransposons. This region completely
encompasses six (NUDT15, MED4, ITM2B, RB1 P2RY5, and RCBTB2) genes and contains
part of a seventh, SUCLA2. Potential NAHR region 2 (1053 kb) is bounded by the
paralogous genes RCBTB1 and RCBTB2. Comparative sequence analysis indicates that the
RCBTB duplication event is quite ancient, but the human RCBTB exonic sequences remain
72% similar. This region completely encompasses nine genes (CYSLTR2, FNDC3A,
MLNR, CDADC1, CAB39L, SETDB2, PHF11, RCBTB1, and RCBTB2). Interestingly,
deletion of RCBTB1 has been suggested to be involved in the development of B-cell chronic
lymphocytic leukemia,79,80 and RCBTB2 is a candidate tumor suppressor for prostate
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cancer.81 Potential NAHR region 3 (67 kb) is smaller than the other two regions and is
bounded by 750- and 745-bp regions with 88% similarity. A total of 73% of the similarity
regions are composed of Alu retrotransposons, and the gene CDADC1 is completely
contained within the region.
The three putative NAHR regions were compared to the deleted regions in our cancer
samples. NAHR regions 1–3 were completely contained within 12, 5, and 26 cancer
deletions, respectively. The positional relationship among the three NAHR regions and
deleted segments could be identified in 39% of bladder cancers, and involved the vast
majority of TCCs demonstrating LOH/LOP in the 13q14 region.
Recombination hotspots that have a propensity toward allelic homologous recombination
may also be involved in NAHR.82 Therefore, we downloaded recombination rates based on
HapMap and Perlegen83 data from UCSC and found seven HapMap recombination hotspots
within the LOP peak that have a recombination rate higher than the average chromosome 13
recombination rate of 1.28 cM/Mb (Figure 11d and e).84
Because Alus are both fairly common and may cause genomic rearrangements implicated in
human diseases,85,86 we scanned the region for Alu content using 10-kb windows (Figure
11f). We found the Alu density upstream of our LOP peak to be consistent with the 10.8%
genome-wide average,87 but the regions bordering this peak showed Alu densities as high as
39.1%.
Human-specific retrotransposons were identified by subtraction using all available
mammalian Alignment Nets compared to human (UCSC Genome Browser) (Figure 11g).
This method detected a human LINE-1 (L1HS) insertion in RB1 that has previously been
shown, in retinoblastoma patients, to result in deletion of RB1 exon 24 through non-
homologous recombination involving an MER repeat.88 Human-specific Alu and SVA
insertions were detected in the introns of NUDT15 and CAB39L, respectively. A human
endogenous retrovirus family H (HERVH) insertion in the LOP peak region was also
detected and may play a role in cancer development.89
We scanned the region for known human polymorphic structural variants consisting
primarily of duplications or deletions (Figure 11h). Several structural variants map to the
interval, which provides further evidence of genomic instability across the region. These
variants were identified in phenotypically normal individuals,90 suggesting that a germline
heterozygous loss of genomic sequence in the region may be associated with an increased
risk for bladder cancer.
Finally, we computed average placental mammal conservation scores in 500-bp windows
across the region along with placental mammal most conserved regions, derived from the 28
species conservation files downloaded from UCSC (Figure 11i and j).91 These
measurements show a region of low conservation within the LOP peak between the RCBTB2
and CYSLTR2 genes. Low conservation implies a lack of functional significance since
functional regions are more conserved. It also implies that this region is highly diverse
across species, suggesting instability over evolutionary time.
Taken together, these analyses suggest a number of potential mechanisms that may be
involved in the generation of allelic losses affecting the RB1 locus. Ongoing analyses are
aimed at finding associations among unique genomic features of the region and risk for
bladder cancer, as well as commonality between the features noted here and the remaining
critical chromosomal regions identified by our WOHGM studies.
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Alternative candidate FR genes mapping near RB1—The minimal region
associated with clonal expansion of in situ neoplasia defined by a 1.34-Mb segment around
RB1 contains 11 positional candidate FR genes. Allelotyping of 100 SNPs mapping to a
3.16-Mb segment in 111 pairs of bladder tumor and PBDNA samples indicates that several
additional genes mapping near the telomeric and centromeric borders of the region should
also be considered positional candidate FR genes.
In our previous studies, we concentrated our efforts on the two neighbor candidate FR genes
flanking RB1, namely ITM2B and RCBTB2 (CHC1L), as well as P2RY5, which is located
inside RB1. We have shown that ectopically driven expression of a wild-type ITM2B, as
well as P2RY5, reduced rates of proliferation in recipient cells and that these effects were
associated with induction of apoptosis, as measured by proteolytic processing of
procaspase-3 and DNA fragmentation. Because the 5′ regions of ITM2B and RCBTB2
(CHC1L) contain CpG islands, we investigated whether methylation of the promoter region
was responsible for silencing these genes in bladder cancer cell lines. Hypermethylation of
the ITM2B promoter was identified in 50% of the cell lines, and was associated with
significant reduction in gene expression. It was also detected in 40% of bladder tumor
samples. We also documented that homozygous inactivation of P2RY5 by allelic loss and
mutation was antecedent to the loss of RB1 in tumor development, and was associated with
expansion of an in situ preneoplastic clone involving large areas of bladder mucosa.
Missense point mutations in P2RY5 were found in 7% of TCC, and some of these mutations
were germline alterations (Figure 12a). One of the polymorphic sites found in P2RY5
(G1722 T) results in substitution of cysteine for tryptophan at position 307, and was detected
in several bladder tumors and non-tumor DNA from the same patient. Molecular modeling
of P2RY5 protein suggested that this substitution involving the cytoplasmic domain of the
protein might affect its interaction with the G-protein complex, and compromise its
biological activity (Figure 12b and c). We documented that the loss of a wild-type 1722 G
P2RY5 allele with retention of the variant 1722 T P2RY5 allele occurred in the in situ phase
of bladder neoplasia and preceded the loss of RB protein expression. We also found that all
1722 G-T carriers who were smokers developed bladder cancer, in a case—control study of
790 patients with bladder cancer.
Since our previously published data indicated that the germline nucleotide substitutions of
P2RY5 might represent a risk factor for hereditary cancer, we sequenced P2RY5 in PBDNA
from index cases of 46 families showing high predisposition for various common
malignancies. We identified a germline mutation of P2RY5 in one of these families (Figure
12d–f). Because several members of this family developed cancers of the breast, colon, lung,
prostate, and uterus, we excluded the involvement of p53 and BRCA1/2 by sequencing of
PBDNA of the same index case, which confirmed wild-type sequences for all the genes.
Given that the P2RY5 gene is located within intron 17 of RB1, we excluded the coexistent
mutation of RB1 by complete sequencing of PBDNA of the same index case, which
disclosed a wild-type sequence for RB1. By testing germline and breast tumor DNAs of
additional members from this family, we showed that the tumors in the affected individuals
had lost the wild-type allele and contained only a mutant P2RY5. The data were not
sufficient for statistical analyses, but the transmission pattern in this family suggested a
cosegregation of P2RY5 germline mutations with the malignant phenotype. Importantly, it
was the whole-organ mapping of bladder cancer that led us to identify P2RY5 germline
mutations.
To further determine whether ITM2B, P2RY5, and RCBTB2 (CHC1L) candidate FR genes
were involved in other cancers besides TCCs, we analyzed their expression, methylation,
and sequence in 62 cell lines derived from several major groups of common human
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malignancies. Of the cell lines tested, at least one of the FR genes was downregulated in
63% of the cases, and ITM2B was methylated in 42%, while mutations of P2RY5 were
detected in 5% (Figure 13). In addition, typically more than one candidate FR gene was
downregulated in a given cell line. Interestingly, the cell lines derived from those tumors in
which RB1 had not been in general implicated in their development, such as colon and
hepatocellular carcinomas,92,93 retained high levels of FR gene expression.
Since our mapping data indicated that 17 genes within and near the minimal deleted region
may represent positional candidate FR genes, we analyzed their expression, sequence, and
methylation status (Table 2). In addition to previously studied ITM2B, P2RY5, and RCBTB2
(CHC1L), the expression pattern of candidate FR genes indicates that GPR38, CAB39L,
RCBTB1, and ARL11 had more than a 50% reduction of their expression in several bladder
cancer cell lines, and should be further investigated as putative FR genes (Figure 14). In
addition to previously published data on ITM2B, P2RY5, and RCBTB2 (CHC1L), a sequence
analysis of new candidate FR genes CYSLTR2, FNDC3A, and MLNR (GPR38) in 12 bladder
cancer cell lines and 20 bladder tumor samples comprising of 10 low-grade (grade 1–2)
superficial (Ta–T1a) and 10 high-grade (grade 3) invasive (T1b and higher) TCCs showed no
evidence of mutational inactivation.
To examine the candidate FR genes for potential epigenetic inactivation by DNA
methylation, we first determined whether their predicted promoters were associated with
CpG islands. Of the 17 genes studied, 14 have CpG islands in their promoter/exon 1 region,
while 4 have CpG poor promoters (P2RY5, CYSLTR2, CAB39L, and ARL11). These latter
four genes were not investigated further for DNA methylation. We determined the
methylation status of the 14 CpG island-associated promoters, using COBRA in a panel of
seven bladder cancer cell lines and SVHUCs. None of the genes were methylated in
SVHUC cells. As previously described, ITM2B was significantly hypermethylated in several
bladder cancer cell lines. Of the remaining 13 genes, 12 were unmethylated in all cell lines
studied. One of the candidate FR genes, MLNR (GPR38), was highly hypermethylated in
five out of seven cell lines and had a low level of methylation in the sixth. In summary, we
identified two candidate FR genes (ITM2B and MLNR) whose CpG islands were
significantly hypermethylated in multiple bladder cancer cell lines, in correlation with
downregulation of their expression. Our data do not exclude the possibility of epigenetic
inactivation of the remaining positional candidate FR genes by other mechanisms such as
chromatin modification. Chromatin modification may be particularly relevant for the
candidate genes that show significant downregulation of their expression but do not contain
CpG islands in their promoters.
The expression pattern of FR genes in multiple cell lines derived from several groups of
human malignancies indicates that their downregulation is frequent in many cancer types.
Hemizygous and homozygous deletions of 13q14 are frequent in a variety of hematopoietic
and solid malignancies. Previously published data suggest the presence of several tumor
suppressor-like candidate genes telomeric to RB1. RCBTB1 and RCBTB2 were implicated in
the development of chronic lymphocytic leukemia and prostate cancer, respectively.78,79
Several recent publications suggest that the inactivation of ARL11 by hypermethylation, and
less frequently by nucleotide substitutions including germline alterations, plays a role in the
development of several common epithelial and hematopoietic malignancies.94–98
THE FR GENE CONCEPT AS RELATED TO BLADDER CARCINOGENESIS
Molecular events involved in the development of bladder cancer have been comprehensively
discussed in several recent reviews.4,5,99–102 In this section, we relate the pathogenesis of
bladder cancer to our mapping data and the concept of FR genes.
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It is generally accepted that human bladder cancer develops via two distinct, but sometimes
overlapping pathways, papillary and non-papillary (Figure 15a–g). The so-called dual-track
concept of bladder carcinogenesis was conceived in the 1970s, and was based on whole-
organ histologic mapping data correlated with the clinical observations.103–106 The distinct
features of papillary and non-papillary types of bladder cancer were subsequently confirmed
by several molecular studies showing that the tumor suppressors and oncogenes were
primarily altered in the high-grade non-papillary pathway.56,73,101,102,107–114 The early
whole-organ mapping studies also suggested that both categories of bladder cancer emerge
from the underlining in situ hyperplastic changes, referred to as LGIN. The similar
frequency of losses in six chromosomal regions associated with the initial expansion of
LGIN, seen in papillary and in non-papillary cancers, is in agreement with these
observations and supports the concept that both pathways start as LGIN characterized by
comparable patterns of chromosomal alterations. Whole-organ genetic mapping also
indicates that the initial in situ expansion involves large areas of bladder mucosa forming
clonal plaques, which clearly exceed the size of physiologic clonal areas seen in normal
urothelium. Such normal clonal areas involve only 1.2 cm2 and comprise approximately 2 ×
106 cells.115
The genome-wide pattern of allelic loss implies a fluctuating rate of events with periods of
instability, followed by relative stability associated with clonal expansion. The sequence of
events is clearly nonlinear and not identical in all tumors. It appears that a limited number of
events have to occur to provide growth advantage for the initial clonal expansion. Among
six chromosomal regions critical for the development of bladder cancer, high-resolution
mapping data are available only for the 13q14 region containing the prototypic tumor
suppressor, RB1. These data show that the loss of genetic material involving the minimally
deleted region flanking the RB1 gene, as well as inactivation of FR genes, is equally
frequent in the superficial papillary and invasive high-grade non-papillary bladder cancers.
Conversely, the inactivation of RB1 is usually a later event, often seen in high-grade non-
papillary invasive TCC (Figure 16a). These observations further support the common origin
of both papillary and non-papillary tumors from the underlying LGIN.
Surprisingly and somewhat contradictory to these observations is the fact that the superficial
papillary and high-grade invasive non-papillary tumors develop in the two distinct clinical
settings; high-grade non-papillary tumors typically present de novo in patients with no
history of superficial papillary tumors. The overlap, however, between the two pathways is
reflected by the progression of superficial low-grade papillary lesions to high-grade invasive
carcinomas. Such progression is preceded by the development of carcinoma in situ within a
papillary lesion or in the adjacent areas of bladder mucosa, and occurs in approximately
15% of patients with a history of low-grade superficial papillary tumor. Consistent with the
development of both pathways in the underlying LGIN and a distinct non-overlapping
clinical presentation in most of the cases is the concept that continuous growth of the
relatively stable LGIN leads to the development of superficial low-grade papillary TCC. In
the high-grade non-papillary pathway, the initial LGIN is genetically unstable and results in
the development of a successor clone or clones, with the inactivated tumor suppressor genes
and microscopic features of HGIN progressing to an invasive high-grade TCC.
Collectively, our data provide evidence that supports the concept and existence of FR genes.
Their loss of function in 13q14 promotes early clonal expansion of in situ neoplasia,
microscopically defined as LGIN, and is antecedent to the loss of RB1 function. In this
phase, the loss of FR genes is responsible for the expansion of the proliferating compartment
that expresses normal RB protein and occupies the entire thickness of in situ neoplasia (see
Figure 15b). In contrast, normal urothelium contains only isolated peribasal cells that
express RB protein. In this scenario, the FR genes provide the initial growth advantage for a
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neoplastic clone, whereas a subsequent loss of a tumor suppressor such as RB1 is a
transforming event associated with the development of HGIN progressing to invasive TCC
(Figure 16b and c). According to this concept, the development of the high-grade aggressive
form of bladder cancer is associated with the loss of FR genes followed by the loss of tumor
suppressor genes and activation of oncogenes. In this model, the continuous growth of
genetically stable LGIN driven by the loss of genes with the FR-like function leads to the
development of low-grade superficial papillary TCC.
CONCLUDING REMARKS
Our map depicts the evolution of genome-wide allelic losses in the development of a
common human cancer, and provides a global look at genome involvement in
carcinogenesis. It shows that each individual cancer developed through distinct patterns of
genetic changes acting in concert with a succession of hits, providing growth advantage that
resulted in clonal expansion and led to a gradual change of normal cells into cancer cells.
116,117 Although much work remains to be done to produce a complete, finished genome-
wide map of bladder cancer development, we believe the significance of these data and their
future applications include the following:
• The overall landscape of genomic alterations emerging from our data implicates a
cumulative complex of allelic losses that occur in early phases of bladder neoplasia,
even before precursor lesions such as dysplasia are microscopically detectable.
However, only a small proportion of these losses demonstrate a close association
with clonal expansion of in situ preneoplastic lesions and their progression to
invasive cancer.
• Targeting of genes mapping to the chromosomal regions involved in clonal
expansion of precursor lesions will help us to understand the early phases of human
carcinogenesis, and may guide our future efforts to develop markers for early
cancer detection and prevention.
• The analysis of human genome sequences spanning the involved chromosomal
regions will not only reveal the gene content but may also provide unique clues to
their structure and apparent instability based on the content of repeat elements, and
other potentially unique evolutionary features. Such data can provide clues to
structural genomic predispositions that lead to the involvement of distinct
chromosomal regions.
• The map presented here should serve as a paradigm for the development of similar
maps defining the development of other human cancers.
• The events of bladder cancer development identified by our studies may also be
relevant to other cancers related to tobacco smoking and industrial or
environmental exposure to chemical carcinogens, such as those that arise in the
lung and upper aerodigestive tract.
The map presented here is but a snap shot of the currently available genome resources. The
rapidly expanding databases of human genomic variation will necessitate a constant
redrawing of the picture. High-resolution allelotyping with SNPs118 should increase the
resolution of our future maps and together with deeper population sequencing to define
nucleotide, insertion/deletion, and copy number variation will help point to which variants
both individually and in combination are involved in the initiation and development of
cancer.
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Figure 1.
Strategy used to construct genomic model of bladder cancer. The primary screening with
hypervariable DNA markers was performed on paired samples of non-tumor and invasive
tumor DNA. Markers showing LOH were selected for secondary screening on all mucosal
samples of the same cystectomy. Markers mapping to autosomes 1–22 were tested on five
cystectomy specimens. The pattern of LOH on chromosomes 1–22 was used to construct a
genome-wide map of bladder cancer development and to identify six chromosomal regions
critical for clonal expansion of in situ neoplasia. Finally, the high-resolution mapping was
performed on one of the critical chromosomal regions containing a model tumor suppressor,
RB1. These studies defined a minimal deleted region associated with clonal expansion of
intraurothelial neoplasia around RB1 and permitted the identification of novel target FR
genes providing growth advantage for this expansion.
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Figure 2.
Organization of the high-resolution mapping studies of 13q14 region. The high-resolution
mapping studies of 26.9 Mb in the 13q14 region containing RB1 were performed with SNP
markers using WOHGM strategy. The frequency of involvement of a 1.34-Mb minimal
deleted region around RB1 was confirmed on 111 samples of bladder tumors by allelotyping
of 100 SNPs mapping across 3.16-Mb segment around RB1. The mapping studies were
followed by the genomic content analysis of the minimal deleted region, as well as
expression, sequencing, methylation, and in vitro functional studies of its positional
candidate FR genes. Some of the studies outlined here were previously published16 and are
complemented with the new analyses included in this paper.
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Figure 3.
Maps of cystectomy specimens used for whole-organ genomic mapping. The distribution of
in situ precursor lesions and TCC is shown in each individual cystectomy according to the
histologic map code. Foci of carcinoma are outlined by a continuous red line. The histologic
grade, pathogenetic subset, and stage for each focus of carcinoma are provided. The
histologic map code is as follows: NU, normal urothelium; MD, mild dysplasia; MdD,
moderate dysplasia; SD, severe dysplasia; CIS, carcinoma in situ; TCC, transitional cell
carcinoma; LGIN, low-grade intraurothelial neoplasia; and HGIN, high-grade intraurothelial
neoplasia.
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Figure 4.
Whole-organ histologic and genetic maps. (a) The histologic map of the entire bladder
mucosa showing a distribution of intraurothelial neoplastic lesions and invasive cancer is
illustrated. For the purpose of statistical analysis, intraurothelial precursor conditions were
classified into two groups: low-grade intraurothelial neoplasia (mild to moderate dysplasia,
LGIN) and high-grade intraurothelial neoplasia (severe dysplasia and carcinoma in situ,
HGIN). The areas of bladder mucosa that were involved by clonal allelic losses of markers
D3S1541 and D12S397 are delineated by interrupted and continuous red lines, respectively.
The positions of these markers on the sex-averaged recombination-based map of
chromosomes 3 and 12 as well as their band positions are shown on the left. (b) Examples of
allelic patterns for the two markers (D12S397 and D3S1541) that were tested on mucosal
samples (numbered 1–13) are illustrated. Sample no. 1 shows the allelic pattern of the same
marker from peripheral blood lymphocytes (PBDNA) of the same patient. (c) Markers
exhibiting clonal losses associated with early and late phases of in situ bladder neoplasia
were identified using a computer algorithm that searched for overlapping plaques that
matched the areas of bladder mucosa, with NU and LGIN contiguous to areas of HGIN and
TCC (gray blocks). The allelic patterns of markers in mucosal samples were compared to
their patterns in peripheral blood lymphocytes of the same patient. The chromosomal
regions showing allelic losses restricted to later phases of neoplasia were identified by an
algorithm that searched for overlapping plaques of losses restricted to HGIN that had
progressed to TCC (red blocks). Markers with non-clonal losses involving smaller
independent areas of the mucosa with no geographic relationship to in situ neoplasia or
invasive cancer were eliminated from the diagram. (Modified and reprinted with permission
from Lee S, Jeong J, Majewski T, et al. Proc Natl Acad Sci USA 2007;104:13732–13737.)
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Figure 5.
Deletion map of chromosome 13 assembled from data generated by whole-organ histologic
and genetic mapping. (a) A list of all tested markers and their positions according to the
updated Cooperative Human Linkage Center Map and their chromosomal band locations is
shown. Markers printed in red showed statistically significant relationship between LOH
and the development of urothelial neoplasia tested by binomial maximum likelihood
analyses and calculated as logarithm of odds (LOD) scores. Red bars on the left side of the
map identify the deleted regions, which are defined by the positions of deleted markers and
their nearest flanking markers with retention of heterozygosity and the predicted size of the
deleted regions in centiMorgans. A chromosomal region containing RB1 flanked by markers
D13S263 and D13S276 spanning 26.9 Mb is oriented with genome sequenced map and the
positions of all known and predicted genes mapping to this region are shown (cM,
centiMorgans; Mb, megabases; WOHGM, whole-organ histologic and genetic mapping of
individual cystectomy specimens consecutively numbered 1 through 8. O – markers with
retention of heterozygosity, ● – markers with LOH, and Ø – non-informative marker). (b)
Summary of binomial maximum likelihood analysis testing the relationship among LOH in
individual chromosome 13 loci and progression of urothelial neoplasia from in situ
precursor conditions to invasive TCC. The allelic patterns of markers in mucosal samples
were compared to their patterns in peripheral blood lymphocytes of the same patient.
Cumulative LOD scores for markers with LOH were calculated at variable θ = (0.01, 0.5,
and 0.99) and tested against Tmax. The significance of allelic losses in individual loci was
analyzed for normal urothelium (NU); low-grade intraurothelial neoplasia (LGIN); high-
grade intraurothelial neoplasia (HGIN), and transitional cell carcinoma (TCC). To simplify
the data, only stringency 1 calculations are presented. The patterns of significant LOD
scores are as described in Materials and methods. Note that significant patterns of LOD
scores typically parallel the high Tmax values (O – LOD score <3; ● – LOD score ≥3).
Deletional maps of chromosomes 1–22 are provided in Supplementary Figure 1.
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Figure 6.
Genome-wide map of bladder cancer progression from intraurothelial precursor conditions
to invasive disease. The map was assembled on the basis of whole-organ histologic and
genetic mapping of chromosomes 1–22. The outer circle represents chromosomal vectors
aligned clockwise from p toq arms with positions of altered markers exhibiting LOH. The
innermost concentric circles represent major phases of development and progression of
urothelial neoplasia from normal urothelium (NU) through low-grade intraurothelial
neoplasia (LGIN), and high-grade intraurothelial neoplasia (HGIN) to transitional cell
carcinoma (TCC). The allelic patterns of markers in mucosal samples were compared to
their patterns in peripheral blood lymphocytes of the same patient. Solid circles (●) denote
statistically significant LOH of the markers defined by the LOD score analysis. Open circles
(○) identify LOH without statistically significant association to a given stage of neoplasia.
The position of open or solid circles on appropriate concentric circles relates the alterations
to a given phase of neoplasia. Only markers with LOH are positioned on the chromosomal
vectors. Solid bars on outer brackets represent clusters of markers with significant LOH and
denote location of putative chromosomal regions involved in urothelial neoplasia. The
distances of markers on chromosomal vectors and the solid bars depicting minimal deleted
regions were adjusted to fit the oval and are not drawn to scale.
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Figure 7.
Genome-wide pattern of LOH identified by WOHGM in a single cystectomy. (a) Three-
dimensional display of the LOH distribution patterns in a single cystectomy specimen. The
vertical axis represents sex-averaged recombination-based chromosomal maps with
positions of hypervariable markers and their chromosomal location. The shaded blocks
represent areas of bladder mucosa with LOH as they relate to the development of bladder
cancer from in situ neoplasia, represented by a histologic map of the cystectomy shown at
the bottom. The allelic patterns of markers in mucosal samples were compared to their
patterns in peripheral blood lymphocytes of the same patient. The histologic map code is the
same as in Figure 3. (b) Clonal losses associated with expansion of in situ neoplasia.
Chromosomal regions exhibiting allelic losses associated with early and late phases of
bladder neoplasia were identified as described in Figure 3.
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Figure 8.
Identification of six critical chromosomal regions involved in the development of bladder
cancer. (a) Genome-wide map of putative critical hits associated with clonal expansion of
intraurothelial neoplasia assembled on the basis of whole-organ histologic and genetic
mapping of chromosomes 1–22 as shown in Figure 4. The outer circle depicts a
recombination-based map of chromosomes arranged clockwise from p to q arms with
positions of markers indicated. The innermost concentric circles represent genetic maps of
the four informative cystectomy specimens. Solid green and red dots denote the positions of
markers with allelic losses in individual specimens associated with clonal expansion of in
situ neoplastic lesions progressing to TCC. Green dots designate markers showing LOH
associated with early clonal expansion that formed large plaques involving TCC, HGIN, and
extended to LGIN or NU. Red dots designate markers with clonal LOH restricted to areas of
HGIN and TCC. The recombination-based maps of six critical chromosomal regions are
expanded and display the positions of their 80 hypervariable DNA markers. The allelic
losses of these markers were tested on DNA extracted from voided urine sediments and
paired peripheral blood DNA of 63 patients with bladder cancer. In 32 patients, voided urine
was collected at the time of initial diagnosis of primary untreated bladder tumor. The
remaining 31 patients had a history of bladder tumor removed by transurethral resection and
were disease free at the time of urine collection. (b) Frequency of allelic losses identified by
individual markers in all 63 DNA samples from voided urine of patients with bladder
cancer. (c) Frequency of LOH in six critical chromosomal regions in patients with clinically
evident tumor and patients with history of bladder cancer and no evidence of disease at the
time of testing. (d) Frequency of LOH in six critical chromosomal regions in low- (grade 1–
2) and high (grade 3)-grade TCCs. (e) Frequency of synchronous involvement of one or
more critical chromosomal regions identified in voided urine in all 63 patients with bladder
cancer. (Modified and reprinted with permission from Lee S, Jeong J, Majewski T, et al.
Proc Natl Acad Sci USA 2007;104:13732–13737.)
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Figure 9.
An example of high-resolution whole-organ mapping by allelotyping of SNPs and the
assembly of LOH distribution patterns within RB1-containing region in a single cystectomy
specimen. (a) The region containing a cluster of SNPs with allelic loss flanked by markers
D13S328 and D13S155 is shown. The bars on the left side indicate the positions of all
known and computationally predicted genes. The blue bars on the right side designate the
positions of informative polymorphic SNPs. The solid black dots and bars designate SNPs
with allelic loss. (b) The genomic map of RB1 is expanded and shows the positions of the
five polymorphic SNPs with allelic loss as well as the positions of two polymorphic DNA
markers (RB1.2 and RB1.20) with allelic loss. (c) The distribution of clonal allelic losses as
they relate to precursor in situ lesions and invasive TCC shown as a histologic map at the
bottom is demonstrated. The blocks depict the distribution of clonal allelic losses identified
by the hypervariable DNA markers (red blocks) and SNPs (gray blocks). The allelic patterns
of SNP markers in mucosal samples were compared to their patterns in peripheral blood
lymphocytes of the same patient. The code for the histologic map is shown in Figure 3. The
hypervariable DNA markers and SNPs with allelic loss associated with plaque-like clonal
expansion involving large areas of bladder mucosa were clustered within and around RB1
and involved approximately 7 Mb. These defined several discontinuous regions of allelic
losses associated with early clonal expansion of urothelial cells that ranged in size from
approximately 0.27–1.11 Mb and are indicated by the vertical blue bars and gray-shaded
areas in (a). The borders and predicted size of these regions were defined by the nearest
flanking SNPs or microsatellite markers that retained polymorphism. The blue numbers
indicate the predicted size of the deleted regions. (d) An example of clonal loss of a G/A
polymorphism in SNP 6 located within intron 12 of RB1 is illustrated. Non-tumor DNA of
peripheral blood lymphocytes of the same patient (PBDNA) shows G/A polymorphism of
SNP 6, while samples corresponding to NU, LGIN, HGIN, and TCC show clonal loss of G.
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Retention of polymorphism in two SNPs flanking a segment of allelic loss that involves the
RB1 gene is also shown. Overall, these data imply that several discontinuous losses of
genetic material, which included RB1 and its flanking regions, occurred in early phases of
bladder neoplasia and were associated with in situ expansion of a dominant neoplastic clone.
(Modified and reprinted with permission from Lee S, Jeong J, Majewski T, et al. Proc Natl
Acad Sci USA 2007;104:13732–13737; (c) and (d) represent new data.)
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Figure 10.
Integration of LOH and LOP patterns identified in the 13q14 region with RB1 sequencing
data and RB protein expression implicating the involvement of FR genes in the
intraurothelial expansion of a neoplastic clone. (a) Regions of LOP associated with early
clonal expansion identified by WOHGM with SNPs in five cystectomy specimens related to
the status of RB1 sequence, RB1(S), and RB protein expression revealed by
immunohistochemistry, RB(IH), are illustrated. The results of RB1 sequencing and
immunohistochemical studies for RB protein expression are tabulated below the maps of
individual bladders. W, wild-type RB1; M, mutant RB1. The mutation in map 2 involved
codon 556 of exon 17 consisting of CGA→TGA and resulting in the change of Arg to a stop
codon. The presence of immunohistochemically detectable RB protein is designated by +.
The absence of RB protein expression is designated by −, and its distribution pattern is
shown in the lower panel of (b). The genome sequence map in which the positions of
hypervariable markers as well as known genes are designated by the bars on the left side of
map. The regions of LOP in five cystectomies (maps 1–5) are depicted by the blue solid
bars. The shadowed areas labeled delA and delB designate the regions of LOP flanking RB1
involved in the incipient expansion of a neoplastic clone. The shaded area labeled delRB1
designates the segment of LOP corresponding to the position of RB1 on the sequence
genome map. (b) The distribution of clonal LOP involving RB1 and the same regions shown
in (a) for map 5 (upper panel) is depicted. The lower panel shows the distribution of the
segment with LOP in map 2 depicted in (a). The code for histologic map is shown in Figure
3. (c) Region of clonal LOP associated with growth advantage of in situ neoplasia identified
by SNP-based mapping. (d) The immunohistochemical pattern of RB protein expression in
representative mucosal samples of map 5 illustrated in (b) as the upper panel and
corresponding to NU, LGIN, HGIN, and TCC is shown. The presence of RB protein in all
mucosal samples correlated with the sequencing data, which indicated that the remaining
wild-type RB1 allele was retained in this case. (e) The immunohistochemical pattern of RB
protein expression in representative mucosal samples of map 2 illustrated in the lower panel
of (b). Positive nuclear staining for RB1 protein in stromal endothelial cells serves as an
internal positive control (arrows). Note the absence of RB protein expression in HGIN and
TCC corresponding to an area containing a mutant RB1 allele. Solid black bars within
photomicrographs indicate 50 μm. (Reprinted with permission from Lee S, Jeong J,
Majewski T, et al. Proc Natl Acad Sci USA 2007;104:13732–13737.)
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Figure 11.
Map of LOP within 3.16-Mb segment around RB1. (a) Allelic losses were tested on 111
paired samples of bladder tumors and peripheral blood using SNP multiplex technology.
Predicted sizes of LOP are depicted as blue bars and a continuous red line shows their
frequency. The genomic map above the diagram shows positions of individual genes (solid
black bars) and tested SNPs (thin black downward bars). Our previously published data
were based on mapping of 84 paired samples of bladder tumor and peripheral blood DNA
with 100 SNPs. The selected SNPs were located primarily inside and around the known and
predicted genes within the tested region with a mapping gap centromeric to RB1 between the
genes HTR2A and SUCLA2. The absence of SNPs spanning a long segment centromeric to
RB1 might have resulted in an artificial shift of the deletion frequency curve telomeric to
RB1. To address this concern, we tested additional eight SNPs spanning a gap between
HTR2A and SUCLA2 and increased the number of tested paired bladder tumor and non-
tumor DNA samples to 111. The pattern and frequency of allelic loss generated by this
approach were almost identical to our previously data16 and implies that the most frequent
breakpoint is located between RCBTB2 and CDADC1. Overall, the pattern of allelic losses
suggests the presence of additional candidate FR genes mapping telomerically to RB1. (b)
The allelic losses are related to histologic grade, RB protein expression, RB1 mutation,
methylation of ITM2B, and nucleotide substitutions of P2RY5, as summarized in the
diagram on the right. Details of RB1 sequencing were published previously.16 L, low grade
(grade 1–2); H, high grade (grade 3); solid blue dots indicate the absence of RB protein
expression, mutation of RB1, methylation of ITM2B, and nucleotide substitutions in P2RY5.
Red crosses indicate tests not performed. (c) Putative NAHR regions identified by the
presence of similar sequences in the same orientation using Human Chained Self Alignment
browser. (d) Recombination rates based on HapMap. (e) Recombination rate based on
Perlegen. (f) Alu repeat content per 10-kb windows. (g) Human-specific retrotransposons
based on UCSC Alignment Nets. (h) Human polymorphic structural variants based on the
Center for Applied Genomics Database of Genomic Variants and the UCSC Structural Var
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track. (i) Placental mammal conservation scores in 500-bp windows. (j) Most conserved
elements, 28-way vertebrate Multiz alignment.
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Figure 12.
Nucleotide substitutions of P2RY5 in sporadic and hereditary cancers. (a) Summary of
sequence analysis of P2RY5. The positions of nucleotide substitutions are shown on the full-
length mRNA. Details of sequencing are provided in Supplementary Table 2. (b) A G-T
polymorphism at codon 307 in the PBDNA resulting in substitution of cysteine for
tryptophan was identified by pyrosequencing (same case as shown in (d)). (c) A model of
inactive P2RY5 containing seven transmembrane (H1–H7) and one cytoplasmic (H8) helix
structures showing the position of polymorphism in codon 307 located within the
cytoplasmic domain of the protein (left diagram) that may affect its interaction with the Gαβγ
trimeric protein complex (right diagram). (d) Pedigree of a family affected by several
common human malignancies that include cancers of the breast, lung, colon, prostate, and
uterus as well as acute leukemia. Sequencing of the peripheral blood DNA in individual IV1
identified a mutation of P2RY5.(e) Wild-type sequence of P2RY5 (upper panel). A missense
G-C mutation involving codon 111 and resulting in substitution of threonine for serine
(S→T) documented by sequencing with subcloning of peripheral blood DNA from
individual IV1 shown in (d) (lower panel). (f) Confirmation of a missense G-C mutation
involving codon 111 of P2RY5 in individuals IV1, IV6, and IV20 by pyrosequencing (same
family as shown in (d)). Note a loss of wild-type P2RY5 allele and retention of a mutant
P2RY5 in breast cancer cells from individual IV1. PBDNA, peripheral blood DNA; Br Ca
DNA, DNA extracted from breast cancer cells microdissected with laser from paraffin-
embedded tissue.
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Figure 13.
Inactivation of FR genes located within and around RB1 is frequent in many cancer types.
Results of quantitative RT-PCR analysis showing relative expression levels of FR genes and
RB1 in 62 cell lines derived from major groups of common human malignancies. The
expression levels of each gene were compared to their baseline expression in the
corresponding normal tissue. The presence of hypermethylation of the ITM2B promoter and
mutations of P2RY5 are summarized below the diagram. The relative expression levels of
FR genes and RB1 were calculated in comparison to the levels of their normal respective
tissues. Note that cell lines derived from colorectal and liver cancers, which in general
develop without involvement of RB1 do not show downregulation of the FR genes. Dashed
lines designate 90% confidence intervals. Details of sequence analysis of P2RY5 are
provided in Supplementary Table 1.
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Figure 14.
Expression pattern of candidate FR genes near RB1. Results of quantitative RT–PCR
showing relative expression of 17 candidate FR genes and RB1 in 12 bladder cancer cell
lines compared to cultured normal urothelial cells (NU204).
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Figure 15.
Dual-track concept of human bladder carcinogenesis. The expansion of preneoplastic clone,
which shows minimal phenotypic deviation from the normal urothelium, is the incipient
event in bladder carcinogenesis referred to as LGIN. In this phase, the loss of FR genes
function provides growth advantage associated with the expansion of proliferating
compartment. The proliferating cells expressing normal RB protein are seen in the entire
thickness of LGIN. In contrast, normal urothelium contains only scattered proliferating cells
expressing RB protein located in its basal layer. The continuous growth of LGIN leads to the
development of low-grade superficial papillary TCC. In the non-papillary pathway, a
successor clone with microscopic features of HGIN often shows a loss of major tumor
suppressors such as RB1 and has a high propensity for progression to an invasive high-grade
non-papillary TCC. (a) Normal urothelium (upper panel). Expression of Ki67 in
proliferating basal cells of normal urothelium (lower panel, left). Expression of RB protein
in peribasal cells of normal urothelium (lower panel, right). (b) Urothelial hyperplasia with
mild atypia referred to as LGIN (upper panel). Expression of Ki67 in the entire thickness of
LGIN (lower panel, left); expression of RB protein in the entire thickness of LGIN (lower
panel, right). (c, d) Low-grade superficial TCC with retention of expression of normal RB
protein: insets to (d) show low- and high-power photomicrographs showing expression of
normal RB protein in low-grade papillary TCC. (e) Severe intraurothelial dysplasia/
carcinoma in situ (HGIN) (upper panel). Loss of RB protein expression in HGIN (lower
panel). (f) High-grade invasive non-papillary carcinoma (upper panel). Loss of RB protein
expression in high-grade invasive non-papillary TCC. Arrow shows expression of RB
protein in endothelial cells adjacent to tumor, which serves as an internal positive control
(lower panel). (g) Severe intraurothelial dysplasia/carcinoma in situ developing in bladder
mucosa adjacent to a low-grade papillary tumor. It is responsible for switching the pathway
and progression of some low-grade papillary tumors to high-grade invasive cancers.
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Figure 16.
Inactivation of FR and RB1 genes in the development of bladder cancer. (a) The analysis of
LOP and inactivation of FR and RB1 genes documented by DNA sequencing, methylation,
and immunohistochemical analyses based on data shown in Figure 12. LGPTCC, low-grade
(grades 1 and 2) superficial (Ta–T1a) papillary TCC; HGNPTCC, high-grade (grade 3) non-
papillary invasive (T1b and higher). (b) Sequential inactivation of P2RY5 and RB1 in the
development of bladder cancer from in situ neoplasia. The loss of wild-type P2RY5 copy
and the retention of the 1722T variant allele inactivate the P2RY5 gene. Low-power view of
invasive bladder cancer and adjacent LGIN and HGIN (upper panel). Microdissected DNA
corresponding to LGIN shows loss of wild-type P2RY5 allele and retention of normal RB
expression pattern (lower panel, left). Microdissected DNA corresponding to HGIN shows
similar loss of wild-type P2RY5 allele and additional loss of RB protein expression (lower
panel, center). Similar loss of wild-type P2RY5 allele and RB protein expression is seen in
invasive TCC (lower panel, right). Arrows indicate retention of normal RB protein
expression in endothelial cells adjacent to tumor. (Reprinted with permission from Lee S,
Jeong J, Majewski T, et al. Proc Natl Acad Sci USA 2007;104:13732–13737.) (c) The FR
gene hypothesis postulates that their inactivation by allelic loss, methylation, and less
frequently by mutations or polymorphism contributes to the initial clonal expansion of in
situ neoplasia microscopically consistent with LGIN common to both papillary and non-
papillary pathways. The loss of tumor suppressor genes, such as RB1, is secondary and
associated with the development of a successor clone showing features of severe dysplasia/
carcinoma in situ (HGIN) progressing to invasive TCC.
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Table 1
Summary of data used for assembly of genome-wide map of bladder cancer
Chromosomes
Average distance
between markers
(cM)
Number
of markers
First screen-
ing (no. of
tests
Secondary
screening
(no. of tests
1 6.86 54 756 819
2 8.26 45 630 925
3 6.70 36 504 289
4 4.77 45 630 900
5 7.83 33 546 1010
6 5.40 42 546 650
7 5.32 43 602 84
8 3.75 43 602 565
9 3.24 52 728 1012
10 5.11 35 490 780
11 3.19 47 658 1163
12 4.91 38 532 73
13 3.03 42 588 789
14 4.80 31 434 163
15 4.89 30 420 98
16 4.52 30 420 646
17 3.79 38 532 1152
18 4.61 29 406 611
19 4.54 23 322 123
20 5.43 21 294 30
21 4.31 16 224 234
22 5.25 14 196 227
Average 5.03 Totals: 787 11 060 12 343
Lab Invest. Author manuscript; available in PMC 2010 April 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Majewski et al. Page 43
Ta
bl
e 
2
Su
m
m
ar
y 
of
 se
qu
en
ce
, e
xp
re
ss
io
n,
 a
nd
 m
et
hy
la
tio
n 
an
al
ys
es
 fo
r 1
7 
po
si
tio
na
l c
an
di
da
te
 F
R
 g
en
es
 a
nd
 R
B1
Se
qu
en
ci
ng
E
xp
re
ss
io
n
M
et
hy
la
tio
n
G
en
e 
na
m
e
D
es
cr
ip
tio
n
Pr
el
im
in
ar
y
L
ar
ge
 sc
al
e
D
ow
nr
eg
ul
at
io
n
C
pG
 is
la
nd
M
et
hy
la
tio
n
SU
C
LA
2
Su
cc
in
at
e-
C
oA
 li
ga
se
N
D
N
D
−
+
−
N
U
D
T1
5
N
ud
ix
-ty
pe
 m
ot
if 
15
N
D
N
D
+
+
−
M
ED
4
M
ed
ia
to
r o
f R
N
A
 p
ol
ym
er
as
e 
II
 tr
an
sc
rip
tio
n
N
D
N
D
−
+
−
IT
M
2B
In
te
gr
al
 m
em
br
an
e 
pr
ot
ei
n 
2B
−
−
+
+
+
RB
1
R
et
in
ob
la
st
om
a 
1,
 tu
m
or
 su
pp
re
ss
or
+
+
+
+
−
P2
RY
5
G
-p
ro
te
in
-c
ou
pl
ed
 P
2Y
5 
re
ce
pt
or
+
+
+
−
N
D
RC
BT
B2
R
C
C
1 
an
d 
B
TB
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 2
−
N
D
+
+
−
C
YS
LT
R2
C
ys
te
in
yl
 le
uk
ot
rie
ne
 re
ce
pt
or
 2
−
N
D
−
−
N
D
FN
D
C
3A
Fi
br
on
ec
tin
 ty
pe
 II
I d
om
ai
n-
co
nt
ai
ni
ng
 3
A
−
N
D
−
+
−
M
LN
R
G
-p
ro
te
in
-c
ou
pl
ed
 re
ce
pt
or
 3
8
−
N
D
+
+
+
C
D
AD
C
1
C
yt
id
in
e 
an
d 
dC
M
P 
de
am
in
as
e 
do
m
ai
n
N
D
N
D
−
+
−
C
AB
39
L
C
al
ci
um
-b
in
di
ng
 p
ro
te
in
 3
9-
lik
e
N
D
N
D
+
−
N
D
SE
TD
B2
SE
T 
do
m
ai
n,
 b
ifu
rc
at
ed
 2
N
D
N
D
−
+
−
PH
F1
1
PH
D
 z
in
c-
fin
ge
r p
ro
te
in
N
D
N
D
−
+
−
RC
BT
B1
R
C
C
1 
an
d 
B
TB
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 1
N
D
N
D
+
+
−
AR
L1
1
A
D
P-
rib
os
yl
at
io
n 
fa
ct
or
-li
ke
 tu
m
or
 su
pp
re
ss
or
 p
ro
te
in
 1
N
D
N
D
+
−
N
D
EB
PL
Em
op
am
il-
bi
nd
in
g 
pr
ot
ei
n-
lik
e
N
D
N
D
−
+
−
K
PN
A3
K
ar
yo
ph
er
in
 a
lp
ha
 3
 (i
m
po
rti
n 
al
ph
a 
4)
N
D
N
D
+
+
−
+,
 id
en
tif
ic
at
io
n 
of
 m
ut
at
io
ns
, d
ow
nr
eg
ul
at
io
n,
 p
re
se
nc
e 
of
 C
pG
 is
la
nd
, a
nd
 m
et
hy
la
tio
n 
of
 th
e 
pr
om
ot
er
, r
es
pe
ct
iv
el
y.
 −,
 N
o 
ev
id
en
ce
 o
f m
ut
at
io
n,
 d
ow
nr
eg
ul
at
io
n,
 C
pG
 is
la
nd
, a
nd
 m
et
hy
la
tio
n 
of
 th
e
pr
om
ot
er
, r
es
pe
ct
iv
el
y.
 N
D
, n
ot
 d
on
e.
 P
re
lim
in
ar
y 
se
qu
en
ci
ng
 w
as
 p
er
fo
rm
ed
 o
n 
fiv
e 
cy
st
ec
to
m
y 
sp
ec
im
en
s u
se
d 
fo
r W
O
H
G
M
, 1
2 
bl
ad
de
r c
an
ce
r c
el
l l
in
es
, a
nd
 2
0 
bl
ad
de
r t
um
or
 sa
m
pl
es
 c
om
pr
is
in
g 
of
 1
0
lo
w
-g
ra
de
 (g
ra
de
s 1
 a
nd
 2
) s
up
er
fic
ia
l (
T a
–T
1a
) a
nd
 1
0 
hi
gh
-g
ra
de
 (g
ra
de
 3
) i
nv
as
iv
e 
(T
1b
 a
nd
 h
ig
he
r T
C
C
s)
 sh
ow
ed
 n
o 
ev
id
en
ce
 o
f m
ut
at
io
na
l i
na
ct
iv
at
io
n.
 L
ar
ge
-s
ca
le
 se
qu
en
ci
ng
 o
f P
2R
Y5
 w
as
pe
rf
or
m
ed
 a
s d
es
cr
ib
ed
 in
 S
up
pl
em
en
ta
ry
 T
ab
le
 2
. T
he
 d
at
a 
on
 la
rg
e-
sc
al
e 
se
qu
en
ci
ng
 o
f R
B1
 in
 b
la
dd
er
 c
an
ce
r w
er
e 
pr
ev
io
us
ly
 p
ub
lis
he
d.
16
Lab Invest. Author manuscript; available in PMC 2010 April 5.
